JNJ

185.96

-1%↓

ABT

125.21

-1.57%↓

MDT

92.25

-1.86%↓

VEEV

288.4

-2.06%↓

A

145.51

-0.68%↓

JNJ

185.96

-1%↓

ABT

125.21

-1.57%↓

MDT

92.25

-1.86%↓

VEEV

288.4

-2.06%↓

A

145.51

-0.68%↓

JNJ

185.96

-1%↓

ABT

125.21

-1.57%↓

MDT

92.25

-1.86%↓

VEEV

288.4

-2.06%↓

A

145.51

-0.68%↓

JNJ

185.96

-1%↓

ABT

125.21

-1.57%↓

MDT

92.25

-1.86%↓

VEEV

288.4

-2.06%↓

A

145.51

-0.68%↓

JNJ

185.96

-1%↓

ABT

125.21

-1.57%↓

MDT

92.25

-1.86%↓

VEEV

288.4

-2.06%↓

A

145.51

-0.68%↓

Search

MacroGenics Inc

Aperta

SettoreSettore sanitario

1.71 -9.52

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.6800000000000002

Massimo

1.88

Metriche Chiave

By Trading Economics

Entrata

4.8M

-36M

Vendite

9M

22M

Margine di Profitto

-162.992

Dipendenti

341

EBITDA

5.7M

-33M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+96.34% upside

Dividendi

By Dow Jones

Utili prossimi

4 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

15M

108M

Apertura precedente

11.23

Chiusura precedente

1.71

Notizie sul Sentiment di mercato

By Acuity

50%

50%

154 / 373 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Neutral Evidence

MacroGenics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

28 ott 2025, 23:50 UTC

Azioni calde

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 ott 2025, 23:25 UTC

Utili

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 ott 2025, 23:18 UTC

Utili

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 ott 2025, 22:20 UTC

Utili

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 ott 2025, 22:13 UTC

Utili

Wal-Mart de Mexico Net Profit Falls in 3Q

28 ott 2025, 21:38 UTC

Utili

Correction to Visa Sales Jump Article

28 ott 2025, 21:17 UTC

Utili

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 ott 2025, 21:07 UTC

Utili

Visa Sales Jump as Consumers Keep Spending -- Update

28 ott 2025, 21:02 UTC

Utili

Mondelez Tempers Outlook as Costs Rise

28 ott 2025, 23:51 UTC

Discorsi di Mercato

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 ott 2025, 23:42 UTC

Discorsi di Mercato

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 ott 2025, 23:02 UTC

Utili

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 ott 2025, 23:01 UTC

Utili

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 ott 2025, 22:46 UTC

Utili

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 ott 2025, 22:45 UTC

Utili

SK Hynix 3Q Net KRW12.6T >000660.SE

28 ott 2025, 22:44 UTC

Utili

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 ott 2025, 22:43 UTC

Utili

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 ott 2025, 22:42 UTC

Utili

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 ott 2025, 22:40 UTC

Utili

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 ott 2025, 22:40 UTC

Utili

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 ott 2025, 22:22 UTC

Utili

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 ott 2025, 22:22 UTC

Utili

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 ott 2025, 22:22 UTC

Utili

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 ott 2025, 22:20 UTC

Utili

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 ott 2025, 22:02 UTC

Utili

Review & Preview: Earnings Extravaganza -- Barrons.com

28 ott 2025, 21:42 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

28 ott 2025, 21:42 UTC

Discorsi di Mercato
Utili

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 ott 2025, 21:20 UTC

Utili

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 ott 2025, 21:19 UTC

Utili

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 ott 2025, 21:18 UTC

Utili

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Confronto tra pari

Modifica del prezzo

MacroGenics Inc Previsione

Obiettivo di Prezzo

By TipRanks

96.34% in crescita

Previsioni per 12 mesi

Media 3.75 USD  96.34%

Alto 5 USD

Basso 3 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per MacroGenics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

6 ratings

3

Acquista

3

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

1.47 / 1.64Supporto e resistenza

A breve termine

Neutral Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

154 / 373 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
help-icon Live chat